1. Pretreatment determination of TPMT – state of the art in clinical practice

   • A. Teml
   • E. Schaeffeler
   • M. Schwab

   Editorial 07 February 2009 Pages: 219 - 221

2. Changes in urinary PGE₂ after ibuprofen treatment in preterm infants with patent ductus arteriosus

   • R. Antonucci
   • L. Cuzzolin
   • V. Fanos

   Clinical Trial 02 December 2008 Pages: 223 - 230

   

3. The effects of problem-based learning integration in a course on rational drug use: a comparative study between two Croatian medical schools

   • Robert Likic
   • Dinko Vitezic
   • Igor Francetic

   Special Article 16 December 2008 Pages: 231 - 237

   

4. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem

   • Yixi Wang
   • Changxi Wang
   • Min Huang

   Pharmacogenetics 21 October 2008 Pages: 239 - 247

   

5. Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients

   • Hua-Wen Xin
   • Hui Xiong
   • Ai-Rong Yu

   Pharmacogenetics 02 December 2008 Pages: 249 - 255

   

6. Distribution of TPMT risk alleles for thioupurine toxicity in the Israeli population

   • Edna Efrati
   • Lior Adler
   • Eli Sprecher

   Pharmacogenetics 02 December 2008 Pages: 257 - 262

   

7. Voriconazole drastically increases exposure to oral oxycodone

   • Nora M. Hagelberg
   • Tuija H. Nieminen
   • Klaus T. Olkkola

   Pharmacokinetics and Disposition 03 October 2008 Pages: 263 - 271

   

8. The pharmacokinetic profile of recombinant human erythropoietin is unchanged in patients undergoing cardiac surgery

   • Stuart A. McCluskey
   • Wing K. Cheung
   • Keyvan Karkouti

   Pharmacokinetics and Disposition 30 October 2008 Pages: 273 - 279

   

9. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers

   • Guo Wang
   • He-Ping Lei
   • Hong-Hao Zhou

   Pharmacokinetics and Disposition 04 November 2008 Pages: 281 - 285

   

10. St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive

    • Liane Will-Shahab
    • Steffen Bauer
    • Axel Brattström

    Pharmacokinetics and Disposition Open access 18 November 2008 Pages: 287 - 294

    

11. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors

    • Anne M. Hausken
    • Kari Furu
    • Jørgen G. Bramness

    Pharmacoepidemiology and Prescription 23 September 2008 Pages: 295 - 301

    

12. Drug use in pregnancy—physicians’ evaluation of quality and clinical impact of drug information centres

    • Sofia Kristina Frost Widnes
    • Jan Schjøtt

    Pharmacoepidemiology and Prescription 04 December 2008 Pages: 303 - 308

    

13. Persistence of antimuscarinic drug use

    • Søren Brostrøm
    • Jesper Hallas

    Pharmacoepidemiology and Prescription 24 December 2008 Pages: 309 - 314

    

14. An analysis of the clinical development of drugs in Norway for the year 2000: the completion of research and publication of results

    • Ola P. Hole
    • Sigurd Nitter-Hauge
    • Finn Ø. Winther

    Debate Article 23 December 2008 Pages: 315 - 318

15. Cytochrome P450 2C19 genetic polymorphisms in Ugandans

    • Jun Miura
    • Celestino Obua
    • Tomonori Tateishi

    Letter to the Editors 11 November 2008 Pages: 319 - 320

16. Hyperthermic intraperitoneal perfusion chemotherapy—views on the observed variability in oxaliplatin pharmacokinetics

    • Nuggehally R. Srinivas

    Letter to the Editors 15 November 2008 Pages: 321 - 322

17. Hypotension due to the drug interaction of voriconazole with eplerenone and nifedipine

    • Jun Kato
    • Takehiko Mori
    • Shinichiro Okamoto

    Letter to the Editors 25 November 2008 Pages: 323 - 324